I'rom Group Co Ltd (2372.T)
1,575JPY
24 May 2019
¥-22 (-1.38%)
¥1,597
¥1,588
¥1,596
¥1,559
189,700
283,362
¥2,479
¥1,370
Latest Key Developments (Source: Significant Developments)
I'rom Group Co Ltd Says To Buy Back Up To 1.12 Percent Of Own Shares Worth 200 Million Yen Through March 29
I'rom Group Co Ltd <2372.T>::I'ROM GROUP CO LTD SAYS TO BUY BACK UP TO 1.12 PERCENT OF OWN SHARES WORTH 200 MILLION YEN THROUGH MARCH 29. Full Article
I'rom Group unit concludes iPS cell generation technology licensing agreement with Evotec International GmbH
May 16 (Reuters) - I'rom Group Co Ltd <2372.T>:Says its unit ID Pharma Co., Ltd. concluded an iPS cell generation technology related licensing agreement with Germany company Evotec International GmbH .Says its unit will receive upfront payment and annual royalty from Evotec International GmbH . Full Article
I'rom Group to set up unit in Hong Kong to management and support co's business in China
Jan 29 (Reuters) - I'rom Group Co Ltd <2372.T>:Says it will set up a Hong Kong-based wholly owned unit, I’ROM LIMITED in February, to management and support the company's business in China .Says the unit will be capitalized at HK$100,000 (about 1.5 million yen). Full Article
I'rom Group unit signs iPS cell tech related license agreement with Q-State Biosciences
Jan 9 (Reuters) - I'rom Group Co Ltd <2372.T>:Says co's wholly owned unit ID Pharma signs iPS cell (induced pluripotent stem cell) technology related license agreement with U.S.-based firm Q-State Biosciences Inc. Full Article
I'rom Group says business and capital alliance with OKWAVE unit
Oct 17 (Reuters) - I'rom Group Co Ltd <2372.T>:Says co signs business and capital alliance agreement with OKWAVE <<<3808.NG>>> unit OKEIOS, which is mainly engaged in medical information handling systems related design, development and sales .Says co plans to acquire shares of OKEIOS. Full Article
I'rom Group fully acquires CMAX Clinical Research Pty for A$6.2 mln
Aug 23 (Reuters) - I'rom Group Co Ltd <2372.T>:* Says it fully acquired 61 percent owned CMAX Clinical Research Pty Ltd for A$6.2 million from IDT Australia Limited on Aug. 23 . Full Article
I'rom Group unit ID Pharma concludes iPS cell generation technology licensing agreement with UK-based Axol Bioscience
July 11 (Reuters) - I'rom Group Co Ltd <2372.T>:Says co's wholly owned unit, ID Pharma, concluded an iPS cell generation technology licensing agreement with UK-based Axol Bioscience Ltd .Says unit grants non-exclusive rights of iPS cell related research, sales and service and sublicense rights to Axol Bioscience Ltd .Says unit will receive upfront payments, iPS cell sales and service related income and royalty from Axol Bioscience Ltd . Full Article
Earnings vs. 
Estimates